← SynDRA
BMS-794833
SynDRA canonical compound SYN0033805 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | BCR |
|---|
| Mechanism of action | Abl kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- Abl kinase inhibitor
- MET INHIBITOR
- Hepatocyte growth factor receptor inhibitor
- KDR INHIBITOR
- Vascular endothelial growth factor receptor 2 inhibitor
- MERTK INHIBITOR
- Bcr-Abl kinase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AXL
- FLT3
- MST1R
- HDAC6
- YES1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ATXN2
- COMT
- CP2C9
- CP2D6
- CP3A7
- GAMT
- GNMT
- HNMT
- IFNG
- KSYK
- NNMT
- NSD2
- PNMT
- SYK
- TP53
Cross-references
Synonyms
- metatinib
- BMS 794833
- BMS794833
- SAY8KVM4HU
- N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxamide
- N-[4-(2-amino-3-chloropyridin-4-yl)oxy-3-fluorophenyl]-5-(4-fluorophenyl)-4-oxo-1H-pyridine-3-carboxamide
- CHEMBL2143592
- N-{4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl}-5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxamide
- UNII-SAY8KVM4HU
- MLS006010952
- SCHEMBL700499
- SCHEMBL13770016
- DTXSID30657662
- EX-A550
- BCPP000323
- HMS3655B10
- BDBM50146164
- MFCD18206786
- ZINC43206812
- AKOS026750476
- BCP9000437
- CCG-264942
- CS-3982
- SB16591
- NCGC00263176-01
- NCGC00263176-03
- NCGC00263176-04
- AC-32814
- AS-75040
- HY-10497
- SMR004702756
- S2201
- SW220169-1
- J-690045
- J-690046
- E0X
- C23H15ClF2N4O3
- orb1305509
- SCHEMBL29542245
Look up BMS-794833 in the interactive SynDRA portal →